These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32184965)

  • 21. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).
    Wang L; Ferrao R; Li Q; Hatcher JM; Choi HG; Buhrlage SJ; Gray NS; Wu H
    J Biol Chem; 2019 Mar; 294(12):4511-4519. PubMed ID: 30679311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling.
    De S; Karim F; Kiessu E; Cushing L; Lin LL; Ghandil P; Hoarau C; Casanova JL; Puel A; Rao VR
    J Biol Chem; 2018 Sep; 293(39):15208-15220. PubMed ID: 30115681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
    Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
    Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
    Degorce SL; Anjum R; Bloecher A; Carbajo RJ; Dillman KS; Drew L; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Rosen A; Scott JS; Xue Y
    J Med Chem; 2019 Nov; 62(21):9918-9930. PubMed ID: 31622099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies.
    Gummadi VR; Boruah A; Ainan BR; Vare BR; Manda S; Gondle HP; Kumar SN; Mukherjee S; Gore ST; Krishnamurthy NR; Marappan S; Nayak SS; Nellore K; Balasubramanian WR; Bhumireddy A; Giri S; Gopinath S; Samiulla DS; Daginakatte G; Basavaraju A; Chelur S; Eswarappa R; Belliappa C; Subramanya HS; Booher RN; Ramachandra M; Samajdar S
    ACS Med Chem Lett; 2020 Dec; 11(12):2374-2381. PubMed ID: 33335659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.
    Nair S; Kumar SR; Paidi VR; Sistla R; Kantheti D; Polimera SR; Thangavel S; Mukherjee AJ; Das M; Bhide RS; Pitts WJ; Murugesan N; Dudhgoankar S; Nagar J; Subramani S; Mazumder D; Carman JA; Holloway DA; Li X; Fereshteh MP; Ruepp S; Palanisamy K; Mariappan TT; Maddi S; Saxena A; Elzinga P; Chimalakonda A; Ruan Q; Ghosh K; Bose S; Sack J; Yan C; Kiefer SE; Xie D; Newitt JA; Saravanakumar SP; Rampulla RA; Barrish JC; Carter PH; Hynes J
    ACS Med Chem Lett; 2020 Jul; 11(7):1402-1409. PubMed ID: 32676146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.
    Murphy M; Pattabiraman G; Manavalan TT; Medvedev AE
    Eur J Immunol; 2017 May; 47(5):880-891. PubMed ID: 28295231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness.
    Qin J; Jiang Z; Qian Y; Casanova JL; Li X
    J Biol Chem; 2004 Jun; 279(25):26748-53. PubMed ID: 15084582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IRAK4 activity controls immune responses to intracellular bacteria Listeria monocytogenes and Mycobacterium smegmatis.
    Pattabiraman G; Murphy M; Agliano F; Karlinsey K; Medvedev AE
    J Leukoc Biol; 2018 Oct; 104(4):811-820. PubMed ID: 29749650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-27a Negatively Modulates the Inflammatory Response in Lipopolysaccharide-Stimulated Microglia by Targeting TLR4 and IRAK4.
    Lv YN; Ou-Yang AJ; Fu LS
    Cell Mol Neurobiol; 2017 Mar; 37(2):195-210. PubMed ID: 26971344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4.
    Patra MC; Choi S
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
    Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
    J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of ulinastatin in reducing lung inflammatory injury in rats with hemorrhagic shock].
    Chen Y; Xu Z; Song Q; Wang Z; Ji Z; Qiu Z; Cheng F; Jiang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1232-1238. PubMed ID: 31801723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
    Seltzer J; Moorad R; Schifano JM; Landis JT; Dittmer DP
    J Virol; 2020 May; 94(10):. PubMed ID: 32161170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TLR2, TLR3 and TLR5 regulation of pro-inflammatory and pro-labour mediators in human primary myometrial cells.
    Lim R; Barker G; Lappas M
    J Reprod Immunol; 2017 Aug; 122():28-36. PubMed ID: 28844021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
    McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
    Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-1 receptor-associated kinase-4 (IRAK4) promotes inflammatory osteolysis by activating osteoclasts and inhibiting formation of foreign body giant cells.
    Katsuyama E; Miyamoto H; Kobayashi T; Sato Y; Hao W; Kanagawa H; Fujie A; Tando T; Watanabe R; Morita M; Miyamoto K; Niki Y; Morioka H; Matsumoto M; Toyama Y; Miyamoto T
    J Biol Chem; 2015 Jan; 290(2):716-26. PubMed ID: 25404736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
    Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
    Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
    J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IRAK4 turns IL-10+ phospho-FOXO+ monocytes into pro-inflammatory cells by suppression of protein kinase B.
    Over B; Ziegler S; Foermer S; Weber AN; Bode KA; Heeg K; Bekeredjian-Ding I
    Eur J Immunol; 2013 Jun; 43(6):1630-42. PubMed ID: 23519847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.